Inventor · disambiguated record
Stefan Jochen Kemmler
Also filed as: KEMMLER STEFAN J · KEMMLER STEFAN JOCHEN
17 granted patents·10 pending applications·73 citations·filing 2014–2025
91Inventor score
Top patents by PatentIndex Score
27 records- 0196US10940192B2Polysaccharide and uses thereofGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2019·Granted Mar 9, 2021·11 cites·20 claims
- 0294US9700612B2Polysaccharide and uses thereofGLYCOVAXYN AG·Filed 2015·Granted Jul 11, 2017·27 cites·20 claims
- 0393US11738076B2Polysaccharide and uses thereofGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2021·Granted Aug 29, 2023·2 cites·22 claims
- 0493US10583185B2Methods and compositions for immune protection against extra-intestinal pathogenic E. coliGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2016·Granted Mar 10, 2020·12 cites·20 claims
- 0593US10441647B2Polysaccharide and uses thereofGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2017·Granted Oct 15, 2019·13 cites·20 claims
- 0692US11446370B2Bioconjugates of E. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereofJANSSEN PHARMACEUTICALS INC·Filed 2020·Granted Sep 20, 2022·6 cites·42 claims
- 0785US12214029B2Polysaccharide and uses thereofGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2023·Granted Feb 4, 2025·0 cites·20 claims
- 0885US11931405B2Bioconjugates of E. coli O-antigen polysaccharides, methods of production thereof, and methods of use thereofJANSSEN PHARMACEUTICALS INC·Filed 2022·Granted Mar 19, 2024·1 cites·22 claims
- 0977US12076385B2Methods and compositions for immune protection against extra-intestinal pathogenic E. coliGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2022·Granted Sep 3, 2024·0 cites·22 claims
- 1076US12233121B2Methods of producing bioconjugates of E. coli O-antigen polysaccharides, compositions thereof, and methods of use thereofJANSSEN PHARMACEUTICALS INC·Filed 2022·Granted Feb 25, 2025·0 cites·8 claims
- 1176US11819544B2Immunogenic compositionGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2018·Granted Nov 21, 2023·1 cites·15 claims
- 1272US2024316172A1Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereofJANSSEN PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1367US2024100140A1Immunogenic compositionGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2023·Application pending·0 cites
- 1466US12128096B2Immunogenic compositionGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2022·Granted Oct 29, 2024·0 cites·13 claims
- 1566US2025222093A1Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereofJANSSEN PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1665US11484582B2Methods and compositions for immune protection against extra-intestinal pathogenic E. coliGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2020·Granted Nov 1, 2022·0 cites·20 claims
- 1764US11491220B2Methods of producing bioconjugates of E. coli o-antigen polysaccharides, compositions thereof, and methods of use thereofJANSSEN PHARMACEUTICALS INC·Filed 2020·Granted Nov 8, 2022·0 cites·6 claims
- 1860US2023293657A1VaccineGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2021·Application pending·0 cites
- 1957US11654190B2Immunogenic compositionGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2018·Granted May 23, 2023·0 cites·5 claims
- 2055US2024139304A1P aeruginosa pcrv-linked antigen vaccinesGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2022·Application pending·0 cites
- 2154US2023226175A1Modified exotoxin a proteinsGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2021·Application pending·0 cites
- 2253US11376314B2Immunogenic compositionGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2018·Granted Jul 5, 2022·0 cites·16 claims
- 2352US2023346902A1Shigella-Tetravalent (Shigella4V) BioconjugateGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2021·Application pending·0 cites
- 2447US2022054632A1Modified carrier proteins for o-linked glycosylationGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2019·Application pending·0 cites
- 2541US2025270520A1Mutated pglb oligosaccharyltransferase enzymesGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2022·Application pending·0 cites
- 2639US11406696B2P aeruginosa PcrV-linked antigen vaccinesGLAXOSMITHKLINE BIOLOGICALS SA·Filed 2016·Granted Aug 9, 2022·0 cites·6 claims
- 2739US2017035900A1Modified host cells and uses thereofGLYCOVAXYN AG·Filed 2014·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Stefan Jochen Kemmler files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →